Abstract
Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS pathophysiology has provided novel treatment approaches with pharmacologic agents capable of manipulating pathways intrinsic and extrinsic to the malignant hematopoietic clone. These advances provide new therapeutic options for patients and provide a basis for further understanding and treatment of this disease.
Keywords: Myelodysplastic syndrome, myeloid, apoptosis, cell cycle, 5q-, cancer stem cell
Current Cancer Therapy Reviews
Title: Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Volume: 2 Issue: 3
Author(s): Eyal C. Attar and Karen K. Ballen
Affiliation:
Keywords: Myelodysplastic syndrome, myeloid, apoptosis, cell cycle, 5q-, cancer stem cell
Abstract: Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS pathophysiology has provided novel treatment approaches with pharmacologic agents capable of manipulating pathways intrinsic and extrinsic to the malignant hematopoietic clone. These advances provide new therapeutic options for patients and provide a basis for further understanding and treatment of this disease.
Export Options
About this article
Cite this article as:
Attar C. Eyal and Ballen K. Karen, Biological Basis of Novel Therapies for Myelodysplastic Syndrome, Current Cancer Therapy Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339406777934708
DOI https://dx.doi.org/10.2174/157339406777934708 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Concise Synthesis of Benzoindolizidine Derivatives and Bioactivity Evaluation
Letters in Organic Chemistry Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry Advances in Fish Cytokine Biology Give Clues to the Evolution of a Complex Network
Current Pharmaceutical Design The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design